Epidemiology and prevention of cancer in older person;Epidemiología y prevención del cáncer en el anciano

Revisiones en Cancer

Volumn 21, Issue 5, 2007, Pages 207-215

  Pérez Manga, Gumersindo ^a   Khosravi Shahi, P ^a   Perez Canon M E ^a  

^a HOSPITAL GENERAL UNIVERSITARIO GREGORIO MARAÑÓN   (Spain)

Author keywords

Aging; Cancer; Elderly; Mortality; Survival

Indexed keywords

PLACEBO; RALOXIFENE; STEROID 5ALPHA REDUCTASE; TAMOXIFEN; TOCOPHEROL; VITAMIN;

AGING; BREAST CANCER; CANCER EPIDEMIOLOGY; CANCER MORTALITY; CANCER RISK; CANCER SCREENING; CANCER SURVIVAL; COLON CANCER; COLORECTAL CANCER; ELDERLY CARE; ENDOMETRIUM CANCER; HUMAN; INCIDENCE; LIFE EXPECTANCY; LUNG CANCER; NEOPLASM; PRIMARY PREVENTION; PROSTATE CANCER; REVIEW; SECONDARY PREVENTION; SPAIN; UTERINE CERVIX CANCER;

EID: 37849030909     PISSN: 02138573     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (68)

1. Madia F, Gatazo C, Fabricio P, Longo VD. A simple model system for age- dependent DNA damage and cancer. Mecanisms of Ageing and Development 2007; 128: 45-9.
2. Kennedy BJ. Aging and cancer. In: Balducci L, Lyman GH, Ershler WbK, editors. Comprehensive Geriatric Oncology. Amsterdan: Harwood Academic Publihsers; 1998. p. 1-6.
3. Hayflick L, Moorhead PS. The serial cultivation of human diploid cell strains, Exp. Cell Res 1961; 25: 585-621.
4. Collado M, Blasco MA, Serrano M. Celular senescente in cancer and aging. Cell 2007; 130: 223-33.
5. Campisi J. Cancer, aging an celular senescente. In vivo 2000; 14: 183-8.
6. Hornsby PJ. Senescence as an anticancer mechanism. J Clin Oncol 2007; 25: 1852-7.
7. Kim SH, Kaminker P, Campisi J. Telomeres, aging and cancer: In search of happy ending. Oncogene 2002; 21: 503-11.
8. Shay JW, Wright WE. Telomeres and telomerase: Implications for cancer and aging. Radiat Res 2001; 155: 188-93.
9. Epel ES, Blackburn EH, Lin J, Dhabhar FS, Adler NE, Morrow JD, et al. Accelerated telomere shortening in response to life stress. Proc Natl Acad Sci. USA 2004; 101: 17312-5.
10. Valdes AM, Andrew T, Gardner JP, Kimura M, Oelsner E, Cherkas LF, et al. Obesity, cigarette smoking and telomere length in women. Lancet 2005; 366: 662-4.
11. Mason PJ, Bessler M. Heterozygous telomerase deficiency in mouse and man: When less is definitely not more. Cell Cycle 2004; 3: 1127-9.
12. Blasco MA. Telomeres and human disease: Ageing, cancer and beyond. Nat Rev Genet 2005; 6: 611-22.
13. von Zglinicki T, Martin-Ruiz CM. Telomeres as biomarkers for ageing and age-related diseases. Curr Mol Med 2005; 5: 197-203.
14. McCormick F. Ras GTPase activating protein: Signal transmitter and signal terminator. Cell 1989; 56: 5-8.
15. Serrano M, Lin AW, McCurrach ME, Beach D, Lowe SW. Oncogenic RAS provokes premature cell senescence associated with accumulation of p53 and p16INKa. Cell 1997; 88: 593-602.
16. Itahana K, Dimri G, Campisi J. Regulation of cellular senescence by p53. Eur J Biochem 2001; 268: 2784-91.
17. Kim SH, Kaminker P, Campisi J. Telomeres, aging and cancer. In search of a happy ending. Oncogene 2002; 21: 503-11.
18. Campisi J. Cellular senescence and apoptosis: How cellular responses might influence aging phenotypes. Exp Gerontol 2003; 38: 5-11.
19. Krtolica A, Parrinello S, Lockett S, Desprez P, Campisi J. Senescent fibroblast promote epithelial cell growth and tumorigénesis: A link between cancer and aging. Proc Natl Acad Sci USA 2001; 98: 12072-7.
20. Bleyer A. Young adult oncology. The patients and their survival challenges. CA. Cancer J Clin 2007; 57: 242-55.
21. National Cancer Institute, U.S. National Institutes of Health. Surveillance, Epidemiology, and End Results (SEER) Program. Available at: www.seer.cancer.gov. Accessed February 4, 2007.
22. Jemal A, Siegel R, Ward HE, Murray T, Xu J, Thun MJ. Cancer Statistics, CA. Cancer J Clin 2007; 57: 43-66.
23. Cancer Incidence in Five Continents, VIII.www.IARC.com/fr
24. López Abente G, Potan M, Aragoneses N, Pérez-Gómez B, et al. Plan integral del cáncer. Situación del cáncer en España. Madrid: Ministerio de Sanidad y Consumo, Septiembre; 2003.
25. INE-INEBASE. Instituto Nacional de Estadística. Mortalidad por cáncer en España. Año 2005.
26. Las personas mayores en España. Instituto de Mayores y Servicios Sociales (IMSERSO). Ministerio de Trabajo y Asuntos Sociales. Madrid; 2006.
27. Lyman GH. Essentials Of. Clinical decision analysis: A new way to think about cancer and aging. In: Balducci L, Lyman GH, Ershler WbK, editors. Comprehensive geriatric oncology. Amsterdan: Harwood Academic Publihsers; 1998. p. 1-6.
28. Walter LC, Covinsky KE. Cancer screening in elderly patients. A framework for individualizad decision making. JAMA 2001: 285: 2750-6.
29. Mandel JS, Bond JH, Church TR, et al. Reducing mortality from colorectal cancer by screening for fecal occult blood. N Engl J Med 1993; 328: 1365-71.
30. Kronborg O, Fenger C, Olsen J, Jorgensen OD, Sondergaard O. Randomised study of screening for colorectal cancer with faecal-occult-blood test. Lancet 1996; 348: 1467-71.
31. Hardcastle JD, Chamberlain JO, Robinson MHE, et al. Randomised controlled trial of faecal-occult-blood screening for colorectal cancer. Lancet 1996; 348: 1472-7.
32. Tabar L, Fagerberg G, Chen H, et al. Efficacy of breast cancer screening by age. Cancer 1995; 75: 2507-17.
33. Kerlikowske K, Grady D, Rubin SM, Sandrock C, Ernster VL. Efficacy of screening mammography: A meta-analysis. JAMA 1995; 273: 149-54.
34. Smith RA, Cokkinides W, Eyre HJ. Cancer screening in United States, 2007. A review of current guidelines, practices and prospects. CA. Cancer J Clin 2007; 57: 90-104.
35. Smith RA, Saslow D, Sawyer KA, et al. American Cancer Society guidelines for breast cancer screening: Update 2003. CA. Cancer J Clin 2003; 53: 141-69.
36. Holmberg L, Lindgren A, Norden T, et al. Age as a determinant of axillary node involvement in invasive breast cancer. Acta Oncol 1992; 31: 533-8.
37. McCarthy EP, Burns RB, Freund KM, et al. Mammography use, breast cancer stage at diagnosis, and survival among older women. J Am Geriatr Soc 2000; 48: 1226-33.
38. McPherson CP, Swenson KK, Lee MW. The effects of mammographic detection and comorbidity on the survival of older women with breast cancer. J Am Geriatr Soc 2002; 50: 1061-8.
39. Rosenberg RD, Hunt WC, Williamson MR, et al. Effects of age, breast density, ethnicity, and estrogen replacement therapy on screening mammographic sensitivity and cancer stage at diagnosis: Review of 183,134 screening mammograms in Albuquerque, New Mexico. Radiology 1998; 209: 511-8.
40. Smith-Bindman R, Kerlikowske K, Gebretsadik T, et al. Is screening mammography effective in elderly women? Am J Med 2000; 108: 112-9.
41. Field LR, Wilson TE, Strawderman M, et al. Mammographic screening in women more than 64 years old: A comparison of 1-and 2-year intervals. Am J Roentgenol 1998; 170: 961-5.
42. Henschke CI, Mc Cauley DI, Yankelevitz DF, et al. Early lung cancer action project: Overall design and findings from baseline screening. Lancet 1999; 354: 99-105.
43. Pastorino U, Bellomi M, Landoni C, et al. Early lung-cancer detection with spiral CT and positron emission tomography in heavy smokers: 2-year results. Lancet 2003; 362: 593-7.
44. Ford LG, Minasian LM, McCaskill-Stevens W, et al. Prevention and early detection clinical trials: Opportunities for primary care providers and their patients. CA. Cancer J Clin 2003; 53: 82-101.
45. International Early Lung Cancer Action Program Investigators, and Henschke CI, Yankelevitz DF, Libby DM, et al. Survival of patients with stage I lung cancer detected on CT screening. N Engl J Med 2006; 355: 1763-71.
46. Powles TJ, Ashley S, Tidy A, et al. Twenty-year follow-up of the Royal Marsden randomized, double-blinded tamoxifen breast cancer prevention trial. J Natl Cancer Inst 2007; 99: 283-9.
47. Cuzick J, Forbes JF, Sestak I, et al. Long-term results of tamoxifen prophylaxis for breast cancer-96-month follow-up of the randomized IBIS-I trial. J Natl Cancer Inst 2007; 99: 272-82.
48. Fisher B, Costantino JP, Wickerham DL, et al. Tamoxifen for the prevention of breast cancer: Current status of the National Surgical Adjuvant Breast and Bowel Project P-1 study. J Natl Cancer Inst 2005; 97: 1652-61.
49. Veronesi U, Maisonneuve P, Rotmensz N, et al. Tamoxifen for the prevention of breast cancer: Late results of the Italian randomized tamoxifen prevention trial among women with cancer. J Natl Cancer Inst 2007; 99: 80-5.
50. Cuzick J, Powles T, Veronesi U, et al. Overview of the main outcomes in breast-cancer prevention trials. Lancet 2003; 361: 296-302.
51. Gail MH, Costantino JP, Bryant J, et al. Weighing the risks and benefits of tamoxifen treatment for preventing breast cancer. J Natl Cancer Inst 1999; 91: 1829-34.
52. Cummings SR, Eckert S, Krueger KA, et al. The effect of raloxifene on risk of breast cancer in postmenopausal women. Results from the MORE randomized trial. JAMA 1999; 281: 2189-94.
53. Cauley JA, Norton L, Lippman ME, et al. Continued breast cancer risk reduction in postmenopausal women treatd with raloxifene: 4-year results from the MORE trial. Multiple outcomes of raloxifene evaluation. Breast Cancer Res Treat 2001; 65: 125-32.
54. Barrett-Connor E, Mosca L, Collins P, et al. Effects of raloxifene on cardiovascular events and breast cancer in postmenopausal women. N Engl J Med 2006; 355: 125-30.
55. Vogel VG, Constantino JP, Wickerham DL, et al. Effects of tamoxifen vs. raloxifene on the risk of developing invasive breast cancer and other disease outcomes. JAMA 2006; 295: 2727-41.
56. Dube C, Rostom A, Lewin G, et al. The use of aspirin for primary prevention of colorectal cancer: A systematic review prepared for the U.S. Preventive Services Task Force. Ann Intern Med 2007; 146: 365-71.
57. Rostom A, Dube C, Lewin G, et al. Nonsteroidal anti-inflammatory drugs and cyclooxygenase-2 inhibitors for primary prevention of colorectal cancer: A systematic review prepared for the U.S. Preventive Services Task Force. Ann Intern Med 2007; 146: 376-81.
58. Giovannucci E, Egan KM, Hunter DJ, et al. Aspirin and the risk of colorectal cancer in women. N Engl J Med 1995; 333: 609-13.
59. Chan AT, Giovannucci EL, Meyerhardt JA, et al. Long-term use of aspirin and nonsteroidal anti-inflammatory drugs and risk of colorectal cancer. JAMA 2005; 294: 914-20.
60. Thompson IM, Goodman PJ, Tangen CM, et al. The influence of finasteride on the development of prostate cancer. N Engl J Med 2003; 349: 215-22.
61. Unger JM, Thompson IM Jr, Leblanc M, et al. Estimated impact of the Prostate Cancer Prevention Trial on population mortality. Cancer 2005; 103: 1375-83.
62. Graver S, Lowensteyn I, Hajek D, et al. Do the benefits of finasteride outweigh the risks in the prostate cancer prevention trial? J Urol 2006; 175: 934-41.
63. Thompson IM, Chi C, Ankerst DP, et al. Effect of finasteride on the sensitivity of PSA for detecting prostate cancer. J Natl Cancer Inst 2006; 98: 1128-35.
64. Andriole GL, Roehrborn C, Schulman C, et al. Effect of dutasteride on the detection of prostate cancer in men with benign prostatic hyperplasia. Urology 2004; 64: 537-43.
65. Andriole G, Bostwick D, Brawley O, et al. Chemoprevention of prostate cancer in men at high risk: Rationale and design of the reduction by dutasteride of prostate cancer events (REDUCE) trial. J Urol 2004; 172: 1314-21.
66. Helzlsouer KJ, Huang HY, Alberg AJ, et al. Association between alpha-tocopherol, gamma-tocopherol, selenium, and subsequent prostate cancer. J Natl Cancer Inst 2000; 92: 2018-24.
67. Eichholzer M, Stahelin HB, Gey KF, et al. Prediction of male cancer mortality by plasma levels of interacting vitamins: 17-year follow-up of the prospective Basel study. Int J Cancer 1996; 66: 145-53.
68. Hartman TJ, Albanes D, Pietinen P, et al. The association between baseline vitamin E, selenium, and prostate cancer in the alpha-tocopherol, beta-carotene cancer prevention study. Cancer Epidemiol Biomarkers Prev 1998; 7: 335-42.